[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354148-105":59,"doc-detail-354148-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","microrna-based-strategies-to-overcome-the-immunotherapy-barrier-in-pancreatic-ductal-adenocarcinoma","MicroRNA-based strategies to overcome the immunotherapy barrier in pancreatic ductal adenocarcinoma","","Pancreatic ductal adenocarcinoma is a highly lethal malignancy with persistent clinical difficulty arising from limited early detection and constrained therapeutic performance. Immunotherapy has benefited many cancers but shows modest efficacy in PDAC due to the immunosuppressive and heterogeneous tumor microenvironment. This review consolidates evidence that microRNAs, as small non-coding regulators with multi-target activity and relatively low toxicity, can shape immune responses and modulate TME dynamics. It evaluates miRNA roles in PDAC, compares miRNA-based therapeutics with conventional approaches, and addresses translation barriers such as off-target effects, toxicity, and delivery, including emerging delivery platforms and integrating AI, soft robotics, and advanced 3D imaging ecosystems.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/microrna-based-strategies-to-overcome-the-immunotherapy-barrier-in-pancreatic-ductal-adenocarcinoma/354148/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/microrna-based-strategies-to-overcome-the-immunotherapy-barrier-in-pancreatic-ductal-adenocarcinoma/354148.png","ImageObject",300,407,{"name":92,"@type":93},"Rizky","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is immunotherapy less effective in pancreatic ductal adenocarcinoma (PDAC)?","Question",{"text":112,"@type":113},"Immunotherapy has limited success in PDAC because the tumor microenvironment is complex and immunosuppressive, reducing effective anti-tumor immune activity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role do microRNAs (miRNAs) play in improving PDAC immunotherapy outcomes?",{"text":117,"@type":113},"miRNAs regulate gene expression with multi-target capabilities, helping modulate immune responses and tumor microenvironment dynamics, which can enhance immunotherapeutic effectiveness.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the main barriers to translating miRNA-based therapies into the clinic?",{"text":121,"@type":113},"Key challenges include off-target effects, toxicity, and delivery barriers. The review also discusses emerging delivery platforms to improve therapeutic efficacy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354148,1790535864,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Review  \nPUBLISHED 28 April 2026  \nDOI 10.3389/fimmu.2026.1744566  \nOPEN ACCESS  \nEDITED BY  \nThomas Enzler,  \nUniversity of Michigan, United States  \nREVIEWED BY  \nAshish Toshniwal,  \nThe University of Utah, United States Zhenhua Li,  \nChina Medical University, China  \n*CORRESPONDENCE  \nJunjie Hu  \n [hero0712@163.com](hero0712@163.com)[ ](hero0712@163.com)Guohua Zheng  \n[zgh1227@sina.com](zgh1227@sina.com)[ ](zgh1227@sina.com)Chen Cheng  \n [ccgina123@hotmail.com](ccgina123@hotmail.com)  \n†These authors have contributed equally to this work  \nRECEIVED 12 November 2025  \nREVISED 30 March 2026  \nACCEPTED 08 April 2026  \nPUBLISHED 28 April 2026  \nCITATION  \nXu H, Wang Q, Cao R, Qiu Z, Liu Y, Hu J, Zheng G and Cheng C (2026)  \nMicroRNA-based strategies to overcome the immunotherapy barrier in pancreatic ductal adenocarcinoma.  \nFront. Immunol. 17:1744566 .  \ndoi: 10.3389/fimmu.2026.1744566  \nCOPYRIGHT  \n© 2026 Xu, Wang, Cao, Qiu, Liu, Hu, Zheng and Cheng. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nMicroRNA-based strategies to overcome the immunotherapy barrier in pancreatic ductaladenocarcinoma  \nHuiwen Xu 1,2,3†, Qi Wang 1,2,3†, Rubin Cao 4, Zhenpeng Qiu 1,2,3, Yuhui Liu 5, Junjie Hu 1,2,3*, Guohua Zheng 1,2,3*  \nand Chen Cheng 2,3,6*  \n1School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China, 2 Hubei Shizhen Laboratory, Wuhan, China, 3Center of Traditional Chinese Medicine Modernization for Liver Diseases, Hubei University of Chinese Medicine, Wuhan, China, 4Wuhan Jiulong Pharmaceutical Co. Ltd, Wuhan, China, 5 Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China, 6 Key Laboratory of Chinese Medicine Resource and Compound Prescription, Ministry of Education, Hubei University of Chinese Medicine, Wuhan, China  \nPancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy that continues to pose a major clinical challenge, primarily due to the difﬁculty of early detection and the limited efﬁcacy of existing therapeutic approaches. Immunotherapy, which has revolutionized the treatment of many other cancers, has shown limited success in PDAC, largely because of the complex and immunosuppressive features of its tumor microenvironment (TME) . Consequently, strategies aimed at remodeling or modulating the TME have emerged as promising avenues for enhancing the therapeutical potential of immunotherapy in PDAC. MicroRNAs (miRNAs), a class of small non-coding RNAs, have emerged as key regulators of gene expression with multi-target capabilities and relatively low toxicity. Increasing evidence demonstrates that miRNAs play critical roles in regulating immune responses and shaping the TME across diverse tumor types, highlighting their considerable potential in improving immunotherapeutic outcomes in PDAC. In this review, we summarize the functional roles of miRNAs in PDAC and discuss the advantages of miRNA-based therapeutics compared with conventional treatments. We further examine current immunotherapeutic strategies for PDAC and highlight how miRNAs regulate immune activity and TME dynamics, providing mechanistic insights into miRNA-mediated immunotherapy. Finally, we discuss the major challenges limiting clinical translation, including offtarget effects, toxicity, and delivery barriers and outline emerging delivery platforms that may enhance therapeutic efﬁcacy. Besides, we explore how emerging technologies, such as artiﬁcial intelligence (AI), miniature soft robotics, and advanced 3D imaging ecosystems can be integ","cbCailqIISmQCvjS","https://ap.wps.com/l/cbCailqIISmQCvjS","pdf",5571822,21,"English","# Introduction\n## Pancreatic cancer burden and epidemiology\n## Risk factors and precursor lesions\n# MicroRNAs and immunotherapy barrier in PDAC\n## Roles of miRNAs in immune activity and TME modulation\n## Advantages of miRNA-based therapeutics\n# Current immunotherapeutic strategies and mechanisms\n## miRNA regulation of immune activity and TME dynamics\n# Challenges and future directions\n## Off-target effects, toxicity, delivery barriers\n## Emerging delivery platforms and integrative technologies","[{\"question\":\"Why is immunotherapy less effective in pancreatic ductal adenocarcinoma (PDAC)?\",\"answer\":\"Immunotherapy has limited success in PDAC because the tumor microenvironment is complex and immunosuppressive, reducing effective anti-tumor immune activity.\"},{\"question\":\"What role do microRNAs (miRNAs) play in improving PDAC immunotherapy outcomes?\",\"answer\":\"miRNAs regulate gene expression with multi-target capabilities, helping modulate immune responses and tumor microenvironment dynamics, which can enhance immunotherapeutic effectiveness.\"},{\"question\":\"What are the main barriers to translating miRNA-based therapies into the clinic?\",\"answer\":\"Key challenges include off-target effects, toxicity, and delivery barriers. The review also discusses emerging delivery platforms to improve therapeutic efficacy.\"}]","MicroRNA-based strategies to overcome the immunotherapy barrier in pancreatic ductal adenocarcinoma | PDF",1790109230,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3796882d50a5675e3da1b3b289fa87ef.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cdca0edcbf61aa5ade06c4a000287f39.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5323308e7450fe30c5a1c8022db41b17.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/237c910f6bfe54c51d9e233ff95b94a4.webp",980,1385]